The Efficacy, Safety, and Satisfaction Associated with Switching from Brinzolamide or Brimonidine to Brinzolamide/Brimonidine in Open-Angle Glaucoma Patients

Hiromitsu Onoe; Kazuyuki Hirooka; Mikio Nagayama; Hideki Mochizuki; Atsushi Hirota; Katsuyoshi Suzuki; Takeshi Sagara; Yoshiaki Kiuchi

doi:10.3390/jpm12122057

The Efficacy, Safety, and Satisfaction Associated with Switching from Brinzolamide or Brimonidine to Brinzolamide/Brimonidine in Open-Angle Glaucoma Patients

J Pers Med. 2022 Dec 13;12(12):2057. doi: 10.3390/jpm12122057.

Authors

Hiromitsu Onoe¹, Kazuyuki Hirooka¹, Mikio Nagayama², Hideki Mochizuki³, Atsushi Hirota⁴, Katsuyoshi Suzuki⁵, Takeshi Sagara⁶, Yoshiaki Kiuchi¹

Affiliations

¹ Department of Ophthalmology and Visual Science, Hiroshima University, Hiroshima 734-8551, Japan.
² Nagayama Eye Clinic, Okayama 714-0086, Japan.
³ Kusatsu Eye Clinic, Hiroshima 733-0861, Japan.
⁴ Hirota Eye Clinic, Yamaguchi 745-0017, Japan.
⁵ Suzuki Eye Clinic, Yamaguchi 755-0155, Japan.
⁶ Sagara Eye Clinic, Yamaguchi 758-0021, Japan.

Abstract

We evaluated switching from brinzolamide 1% or brimonidine 0.1% to a fixed-combination of brinzolamide 1% and brimonidine 0.1%, and then determined the efficacy, safety, and satisfaction associated with these changes in glaucoma patients. This prospective, nonrandomized study evaluated a total of 31 enrolled glaucoma patients who underwent treatment with at least brinzolamide 1% or brimonidine 0.1%. Patients were administered a brinzolamide/brimonidine fixed-combination ophthalmic suspension (BBFC) after being switched from their original brinzolamide 1% or brimonidine 0.1% therapy. All other intraocular pressure (IOP)-lowering medications currently being used were continued. IOP, superficial punctate keratopathy (SPK), and conjunctival hyperemia data obtained at baseline and then at 4 and 12 weeks were evaluated. To assess the changes in treatment satisfaction, this study utilized the Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9). There was a significant decrease in the mean baseline IOP from 15.7 ± 4.9 mmHg to 13.6 ± 4.4 (p = 0.001) and 13.5 ± 3.9 mmHg (p = 0.002) at 4 and 12 weeks, respectively. Evaluation of the incidence of conjunctival hyperemia or SPK score showed there were no significant changes noted at any time point. The TSQM-9 score demonstrated there was a significant increase for effectiveness after switching from brinzolamide 1% or brimonidine 0.1% to BBFC. After switching from brinzolamide 1% or brimonidine 0.1% to BBFC, there was a significant decrease in the IOP. Patients were aware of the effectiveness of switching from brinzolamide 1% or brimonidine 0.1% to BBFC.

Keywords: brimonidine; brinzolamide; glaucoma; satisfaction.

Grants and funding

This research was funded by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (20K09827).